⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Supplemental Figure 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Leanne G. Ahronian Soumyadip Sahu Minjie Zhang Ayushi S. Patel Ke Geng Reshmee Bhattacharya Gerald S. Falchook Jonathan W. Goldman Alexander I. Spira Salman R. Punekar David R. Spigel Judy S. Wang Ferdinandos Skoulidis Janaye Stephens Mary Meynardie Jaylen M. Powell Alfonso Lopez Michela Ranieri Magdalena A. Ploszaj Yi Jer Tan Yeuan Ting Lee Yi Yu Jiehui Deng Ting Chen Patrick McCarren Alice Tsai Suleman S. Hussain Brian Doyon Kenjie Amemiya Jacques Ermolieff Preksha Shahagadkar Nikitha M. Das Lauren R. Flynn Julie A. Shields Laney Danielczyk Brian J. McMillan Andre Mignault Samuel R. Meier Hsin‐Jung Wu David J. Guerin Douglas A. Whittington Chengyin Min Iga Sienczylo John P. Maxwell Heather DiBenedetto Hideo Watanabe Brian B. Haines Alan Huang Adam Crystal Jannik N. Andersen Xinyuan Wu Kwok‐Kin Wong

View at Publisher

Ask AI

Bookmark

Share

Key Points

TNG260 significantly enhances the effectiveness of anti-PD-1 immunotherapy in tumors with STK11 mutations.
Research indicates that TNG260 selectively targets HDAC3-9 and HDAC11, playing a crucial role in treatment outcomes.
Observational analysis showcases how CoREST inhibition may alter resistance patterns in mutant tumors during immunotherapy.
These findings suggest potential for integrating TNG260 with existing therapies, warranting further clinical exploration.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Evaluation reveals CoREST inhibitor enhances anti-PD-1 efficacy in STK11-mutant tumors, suggesting new therapeutic avenues.

Abstract

TNG260 is selective against HDAC3-9, 11

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahronian et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcac9 https://doi.org/10.1158/0008-5472.30363298

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
2Supplemental Figure 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
3Supplemental Figure 9 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
4Supplemental Figure 7 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
5Supplemental Table 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
6Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
7Supplemental Table 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
8Supplemental Table 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025